📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Arrevus

1.1 - Company Overview

Arrevus Logo

Arrevus

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of investigational therapies for Farber disease and serious infections. Based in Research Triangle Park, Arrevus develops ACG-801, an enzyme replacement therapy addressing acid ceramidase deficiency, and ACG-701, a novel oral antibiotic for melioidosis caused by B. pseudomallei with a unique dosing regimen and for acute cystic fibrosis-related pulmonary exacerbations.

Products and services

  • ACG-701 (Cystic Fibrosis): A novel oral antibiotic targeting acute treatment of cystic fibrosis-related pulmonary exacerbations in patients with cystic fibrosis
  • ACG-701 (Melioidosis): An investigational oral antibiotic for treating melioidosis, caused by B. pseudomallei, with a unique dosing regimen
  • ACG-801: An investigational enzyme replacement therapy for Farber disease, aiming to address acid ceramidase deficiency implicated in Farber disease

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Arrevus

Stat-Dx Logo

Stat-Dx

HQ: Spain Website
  • Description: Provider of near-patient testing products for healthcare professionals, primarily for short turnaround time applications and critical care.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Stat-Dx company profile →
Achillion Pharmaceuticals Logo

Achillion Pharmaceuticals

HQ: United States Website
  • Description: Provider of biopharmaceutical therapies targeting the complement system, including Soliris for paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS) and neuromyelitis optica spectrum disorder; Ultomiris, a long-acting C5 complement inhibitor, for PNH, aHUS, generalised myasthenia gravis and NMOSD; and Strensiq for hypophosphatasia.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Achillion Pharmaceuticals company profile →
F2G Logo

F2G

HQ: United Kingdom Website
  • Description: Provider of novel antifungal drug discovery and development, advancing patented compounds and technologies to treat life-threatening fungal diseases. Founded on proprietary genomics technology (MycoBank) that identifies essential gene targets in fungi.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full F2G company profile →
Scynexis Logo

Scynexis

HQ: United States Website
  • Description: Provider of drug discovery, development and manufacturing projects focused on antifungal therapeutics, including ibrexafungerp, a novel oral/IV glucan synthase inhibitor for serious and resistant fungal infections; SCY-247, a second-generation broad-spectrum triterpenoid; VVC and RVVC treatments; and the MARIO study evaluating oral step-down after IV echinocandin for invasive candidiasis and candidemia.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Scynexis company profile →
Genelabs Technologies Logo

Genelabs Technologies

HQ: United States Website
  • Description: Provider of biopharmaceutical R&D focused on discovering and developing therapies for infectious diseases, offering drug discovery services and medications including Morphine for severe pain, Atomoxetine (Strattera) for ADHD, Finasteride (Propecia) for male pattern hair loss, and Valacyclovir (Valtrex) for herpes and shingles.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Genelabs Technologies company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Arrevus

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Arrevus

2.2 - Growth funds investing in similar companies to Arrevus

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Arrevus

4.2 - Public trading comparable groups for Arrevus

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Arrevus

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Arrevus

What does Arrevus do?

Arrevus is a provider of investigational therapies for Farber disease and serious infections. Based in Research Triangle Park, Arrevus develops ACG-801, an enzyme replacement therapy addressing acid ceramidase deficiency, and ACG-701, a novel oral antibiotic for melioidosis caused by B. pseudomallei with a unique dosing regimen and for acute cystic fibrosis-related pulmonary exacerbations.

Who are Arrevus's competitors?

Arrevus's competitors and similar companies include Stat-Dx, Achillion Pharmaceuticals, F2G, Scynexis, and Genelabs Technologies.

Where is Arrevus headquartered?

Arrevus is headquartered in United States.

How many employees does Arrevus have?

Arrevus has 1,000 employees 🔒.

When was Arrevus founded?

Arrevus was founded in 2010 🔒.

What sector and industry vertical is Arrevus in?

Arrevus is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Arrevus

Who are the top strategic acquirers in Arrevus's sector and industry

Top strategic M&A buyers and acquirers in Arrevus's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Arrevus?

Top strategic M&A buyers groups and sectors for Arrevus include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Arrevus's sector and industry vertical

Which are the top PE firms investing in Arrevus's sector and industry vertical?

Top PE firms investing in Arrevus's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Arrevus's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Arrevus's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Arrevus's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Arrevus include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Arrevus's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Arrevus?

The key public trading comparables and valuation benchmarks for Arrevus include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Arrevus for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Arrevus with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Arrevus's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Arrevus with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Arrevus's' sector and industry vertical?

Access recent funding rounds and capital raises in Arrevus's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Arrevus